Oncovet® CL, bombe tablets, scored on one side of 2 mg, 5 mg, 10 mg, 20 mg purple color. In individual cases with a non-toxic homopolymer polypropylene container, with a purple RP-28 lid containing 20 tablets, in the following presentations:
Oncovet® CL - Chlorambucil 2 mg - 1 bottle of 20 tablets per carton.
Oncovet® CL - Chlorambucil 5 mg - 1 bottle of 20 tablets per carton.
Oncovet® CL - Chlorambucil 10 mg - 1 bottle of 20 tablets per carton.
Oncovet® CL - Chlorambucil 20 mg - 1 bottle of 20 tablets per carton.
Indications for use: Oncovet® CL is indicated for the treatment of cancer patients and immune-mediated diseases. Chlorambucil is used in canines mainly for the treatment of cancer patients suffering from lymphomas, chronic lymphocytic leukemia, thymoma, salivary gland neoplasms, mast cell tumors, multiple myeloma, ovarian adenocarcinoma, traditional cell carcinoma of the bladder, and for immune-mediated diseases such as enteropathy immune-mediated chronic disease, inflammatory bowel disease, polycythemia vera and macroglobulinemia, autoimmune glomerulonephritis, pemphigus foliaceus and myasthenia gravis and in felines with oncological diseases in lymphoma, leukemia and immune-mediated conditions such as pemphigus foliaceus, pemphigus complex, Bowel disease, peritonitis and idiopathic pruritus.
Properties and pharmacological action: It is an alkylating agent from the group of nitrogen mustards and constitutes an aromatic analog, which results from the addition of aminophenylbutyric acid.
Mechanism of action: At the cellular level it reacts with the nitrogenous bases of DNA and gives rise to the formation of inter-chain and intra-chain bridges, responsible for the functional alteration of DNA and, ultimately, cell death. It is most sensitive in the late G1 and S phases of the cell cycle.
Malignant neoplasms are characterized by accelerated cell division, which is no longer regulated as in the cell division of healthy tissues. "Normal" cells stop dividing when they come into contact with similar cells, a mechanism known as contact inhibition. Cancerous cells lose this ability. In cancer cells, the self-regulatory system that controls and limits cell division (among others) is unbalanced. The process of cell division, whether in normal or cancer cells, takes place through the cell cycle. This cycle goes from the resting phase, through the phases of active growth, to mitosis.
The ability of chemotherapy to kill cancer cells depends on its ability to stop cell division. Usually, drugs work by damaging the RNA or DNA that tells the cell how to make a copy of itself in division. If the cells can not divide, they die. The faster the cells divide, the more likely the chemotherapy will kill the cells and the tumor will shrink. In addition, these drugs induce cell suicide (programmed cell death or apoptosis).
Chemotherapy drugs that kill cells only during division are called cell cycle specific. Chemotherapy drugs that kill cancer cells during the resting phase are called cell cycle nonspecific. Chlorambucil is classified as an alkylating agent. Alkylating agents reach their highest level of activity during the cell rest phase. These types of drugs are not specific to the cell cycle. Chemotherapy is scheduled based on the type of cells, how fast they are dividing, and when a given drug is likely to be effective. It is for this reason that chemotherapy is usually given in cycles.
Chemotherapy is very effective at destroying rapidly dividing cells. Unfortunately, chemotherapy does not recognize the difference between cancer cells and normal cells. The "normal" cells will grow back, but in the meantime there are side effects. The "normal" cells most often affected by chemotherapy are blood cells, those found in the mouth, stomach, and intestine, as well as hair follicles; This causes low blood counts, oral problems, nausea, diarrhea mainly.
Dosage (general): Oncovet® CL doses vary depending on the reason for the disease and the degree of progression of the disease. The dose in each patient must be calculated by the veterinary oncologist or immunologist, according to certain variables such as: clinical stage of the animal with cancer or immune-mediated disease, results of the histopathological study, other complementary studies, and concomitant diseases or conditions of the animal.
Number of administrations: The duration and quantity of administrations depends on the condition to be treated, the response to the medication and the development of adverse effects. It must be calculated by the veterinary oncologist, according to certain variables such as: clinical stage of the animal with cancer or immune-mediated disease, results of the histopathological study, other complementary studies, and concomitant diseases or conditions of the animal. In general the induction phase are cycles of between 14 - 21 days; and the maintenance phase several months (average 6 months).
Contraindications and limitations of use: Chlorambucil should not be used in animals with known hypersensitivity to it or that have demonstrated resistance to its effects. Chlorambucil should not be used in pregnant animals. This drug can severely suppress bone marrow function and should not be used in patients with pre-existing depression or infection. Anemia, leukopenia, and thrombocytopenia can occur as a result of Chlorambucil treatment. It can cause myoclonus in cats.
Exclusive use in Veterinary Medicine.
Sale with Archived Veterinary Prescription (Cat. II).
Its fractional sale is prohibited.
Use in Canines and Felines.
Expiration: 2 years from the moment of its elaboration.
Keep out of the reach of children and pets.
Used containers must be discarded according to current local legislation.
Store at temperatures between 2 and 8ºC
CHEMOVET VETERINARY PHARMACEUTICAL LABORATORY
9 de Julio 3875, Lanús, Buenos Aires, Argentina.
Registration number (SENASA): 12,197